# A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment

Source: https://onco.cc/trials/nct04576156/  
OnCo record `nct04576156` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Imetelstat in myeloproliferative neoplasms, run by Geron Corporation, active and no longer recruiting.

## Summary

A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment is a phase 3 interventional study registered as NCT04576156 by Geron Corporation, with 327 participants enrolled, started 2021-04-12 and due to reach its primary completion in 2028-06-30. Interventions recorded: Imetelstat and Best Available Therapy (BAT).

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04576156
- Phase: 3
- Setting: A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients With Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/R) to Janus Kinase (JAK) Inhibitor
- Sponsor: Geron Corporation
- Enrolled: 327

## Sources

- ClinicalTrials.gov NCT04576156: https://clinicaltrials.gov/study/NCT04576156

## Connected records

- cancers: [Myeloproliferative neoplasms (PV, ET, myelofibrosis)](https://onco.cc/cancers/myeloproliferative-neoplasms/)
- drugs: [Imetelstat](https://onco.cc/drugs/imetelstat/)
- companies: [Geron Corporation](https://onco.cc/companies/geron/)

---
JSON: https://onco.cc/api/v1/entities/nct04576156.json